Teewinot Capital Advisers’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-26,125
Closed -$1.33M 34
2025
Q4
$1.33M Hold
26,125
0.1% 31
2025
Q3
$1.45M Sell
26,125
-10,372
-28% -$607K 0.11% 34
2025
Q2
$2.52M Hold
36,497
0.21% 23
2025
Q1
$2.53M Hold
36,497
0.26% 22
2024
Q4
$3.14M Buy
+36,497
New +$3.95M 0.32% 20

Other funds holding NVO

Teewinot Capital Advisers's NVO Position: Q1 2026 in Review

Teewinot Capital Advisers sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 26,125 shares — an estimated $1.33M sold.

Teewinot Capital Advisers first reported a position in NVO in Q4 2024 and held it in 5 quarters. The position peaked at $3.14M in Q4 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Teewinot Capital Advisers reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Teewinot Capital Advisers sold 26,125 Novo Nordisk shares in Q1 2026, an estimated $1.33M.
  • Teewinot Capital Advisers first reported a position in Novo Nordisk in Q4 2024 and held it in 5 quarters.
  • Teewinot Capital Advisers's Novo Nordisk position peaked at $3.14M in Q4 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Teewinot Capital Advisers's 13F filing for Q1 2026, filed 15 May 2026.